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ABSTRACT
Objective
In this paper, we set out to describe the personal and
social contexts of treatment decisions made by cancer
patients concerning complementary and alternative
medicine (CAM) and also the process through which
cancer patients reach CAM decisions throughout the
cancer trajectory.
Methods
We selected and reviewed a variety of CAM decision-
making models published in the past 10 years within
the Canadian health literature.
Results
The CAM decision-making process is influenced by a
variety of sociodemographic, disease-related, psycho-
logical, and social factors. We reviewed four main
phases of the CAM decision-making process:
• Taking stock of treatment options
• Gathering and evaluating CAM information
• Making CAM decisions
• Revisiting the CAM decision
Immediately following diagnosis, cancer patients
become interested in taking stock of the full spectrum
of conventional and CAM treatment options that may
enhance the effectiveness of their treatment and me-
diate potential side effects. Information about CAM is
then gathered from numerous information sources that
vary in terms of credibility and scientific legitimacy,
and is evaluated. When making a decision regarding
CAM options, patients attempt to make sense of the
diverse information obtained, while acknowledging
their beliefs and values. The CAM decision is often re-
visited at key milestones, such as the end of conven-
tional treatment and when additional information about
disease, prognosis, and treatment is obtained.
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Conclusions
The CAM decision-making process is a dynamic and
iterative process that is influenced by a complex array
of personal and social factors. Oncology health pro-
fessionals need to be prepared to offer decision sup-
port related to CAM throughout the cancer trajectory.
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1. INTRODUCTION
Since the late 1990s, a growing number of studies have
focused on the engagement of cancer patients in the
treatment decision-making process 1–4. The use of
qualitative research methods has provided a greater
understanding of how cancer patients make sense of
the treatment recommendations provided by their health
professionals, and of the process by which they seek
additional information and evaluate the risks and ben-
efits of available treatment options 5–8. Individuals liv-
ing with cancer have varying needs regarding their
preferred level of involvement in treatment decisions,
and correspondingly, vary in the way in which they can
be best supported by health professionals during the
decision-making process 9,10. Although previous re-
search has provided insight into the decision-support
strategies required by patients faced with conventional
treatment decisions, its applicability to patients mak-
ing decisions about complementary and alternative
medicine (CAM) is questionable.
The literature suggests that most Canadian cancer
patients use CAM at some point during their illness 11,12.
It is therefore essential that oncology health profes-
sionals understand and acknowledge the unique con-
texts and processes that influence treatment decisions
specific to CAM for each patient. This acknowledg-
ment is especially important given the emerging field
of integrative oncology in North America, in which
evidence-based CAM therapies are gradually beingBALNEAVES et al.
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integrated into mainstream cancer care 13. Decision-
support strategies that facilitate patients’ informed use
of CAM and full disclosure of CAM use with health pro-
fessionals are essential for the safe integration of CAM
with conventional cancer care.
Canadian researchers have taken a leading role in
examining the treatment decision-making process of
cancer patients interested in CAM 14–18. This work has
resulted in the development of several decision-mak-
ing models that capture the complex interplay between
key personal, social, and cultural factors and the cog-
nitive processes that underlie the CAM decision-mak-
ing process. Although these models have been limited
mainly to breast and prostate cancer and have yet to be
empirically tested, they provide health professionals
with insight into the experiences of patients making
CAM decisions, and they highlight moments during the
cancer trajectory when patients may possibly benefit
most from decision support.
In the present paper, we begin our discussion by
highlighting the highly complex, dynamic, and individu-
alized nature of CAM decisions, which results from the
unique personal, social, and cultural contexts in which
these decisions are embedded. We then draw on previ-
ous decision-making models and provide a summary
of the main stages within the CAM decision-making
process (Figure 1):
• Taking stock of treatment options
• Gathering and evaluating CAM information
• Making a decision
• Revisiting the decision
This overview emphasizes the iterative nature of
the CAM decision-making process and how it unfolds
across the cancer trajectory.
2. DISCUSSION
2.1 The Context of CAM Decisions
The decision about whether to use CAM, and if so, the
type or types of CAM to use, is influenced throughout
the cancer trajectory by a myriad of factors that can be
grouped as follows: sociodemographic and disease-re-
lated factors, psychological factors, and social factors.
2.1.1 Sociodemographic and Disease-Related Factors
At a basic level, specific demographic and disease-
related factors have been found to be associated with
CAM use, including age (younger), sex (women), and
socio-economic status (higher education and income)
19–21. These personal factors have been identified as
being predictive of other self-care health behaviours
and reflect health care access issues and the increased
use of health care services by women 22. Further, de-
spite an increasing number of private health insurance
plans providing coverage for specific CAM practices
(such as acupuncture and chiropractic treatment), many
CAM therapies are not covered through public or pri-
vate health insurance. As a result, the decision to use
CAM can be an expensive undertaking for many pa-
tients, particularly those who are on disability as a re-
sult of their illness.
In Canada’s multicultural society, it is also impera-
tive to acknowledge the important influence that
ethnicity may have on CAM use. For a growing num-
ber of immigrants and indigenous peoples, traditional
medical systems (for example, Traditional Chinese
Medicine, Ayurveda, First Nations traditional heal-
ing) are the primary source of health care. As a re-
sult, many cancer patients arrive at initial consultations
already using or interested in trying CAM therapies
that are not considered “alternative” within their
ethnocultural community.
Increased CAM use has also been related to dis-
ease characteristics. It has been observed to be higher
in breast and prostate cancer populations than in popu-
lations with other cancer diagnoses 20,23. The height-
ened interest in CAM in these populations may be a
consequence of the proactive nature of these patient
groups with regard to advocacy and self-care (that is,
support-group membership). Cancer patients with ad-
vanced disease have also been found to have a height-
ened interest in CAM 24, which may reflect their attempt
to maintain hope when presented with a poor progno-
sis and limited conventional treatment options, coupled
with a search for healing when cure is not possible.
Lastly, CAM therapies that require intensive time and
energy, such as restrictive diets or frequent visits to a
practitioner, may be impractical for patients undergo-
ing active cancer treatment, particularly for those ex-
periencing fatigue or other debilitating physical or
psychological symptoms.
2.1.2 Psychological Factors
Equally influential in the CAM decision-making pro-
cess are psychological factors. For many individuals,
the initial decision to explore CAM treatment options
arises from a strong internal locus of control (that is,
FIGURE 1 The complementary and alternative medicine (CAM)
decision-making process.PATIENT DECISION-MAKING ABOUT CAM
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the tendency to attribute event outcomes to one’s own
control 25) and a desire to be an active participant in
treatment decisions 18,26–29. In addition, for some pa-
tients, CAM therapies may also provide the hope and
optimism required to cope with the cancer journey 18,30.
For others, their fears about death and dying may mo-
tivate their search for treatment options beyond con-
ventional cancer care so that they can “cover all their
bases” 18,31.
2.1.3 Social Factors
It is important to recognize how the personal and psy-
chological factors associated with CAM use are also
embedded within a larger social context that legitimizes
and reinforces the exploration and use of many CAM
therapies. For example, the increasing tendency of
cancer patients to consider CAM as a treatment option
during their illness may reflect the currently persistent
postmodern ideals of individualism, consumerism, and
holism 32,33. In addition, an individual’s understand-
ings of what constitutes appropriate treatment and how
it can best be achieved are derived not only from per-
sonal experience, but also from social interaction and
interface with cultural products—most notably the mass
media 32. Information about CAM is increasingly avail-
able and accessible through media sources 34, which
lend visibility and perceived legitimacy to this group
of therapies and practices.
Further, male and female cancer patients both de-
scribe family members, friends, and fellow cancer
survivors to be highly influential in their CAM deci-
sions 15,16,35,36. Members of a patient’s social network
can take on a variety of decision-support roles depend-
ing on a patient’s diagnosis and stage of illness, and
the nature of their relationship with the patient 35,36.
These roles include “interested bystander” (a person
who listens and supports a patient’s CAM decisions),
“information gatherer and reviewer” (a person who
helps collect and evaluate information), and “direc-
tor” (a person who takes over the decision-making pro-
cess on behalf of the patient) 36.
2.2 The CAM Decision-Making Process
Unlike the many rational treatment decision-making
models presented within the health care literature, the
CAM decision-making process has been described as a
dynamic and iterative process that is highly variable
across individuals 14,15,18. Despite its complex, non-
linear, and individualized nature, some common stages
of the CAM decision-making process can be explicated.
2.2.1 Taking Stock of Treatment Options
Research has shown that the CAM decision-making
process begins immediately following a diagnosis of
cancer 14,15,18. Despite being emotionally over-
whelmed by the news of their diagnosis, most cancer
patients are eager to learn about the full spectrum of
treatment options and often do not distinguish between
conventional and complementary therapies 18. At the
time of diagnosis, patients are particularly interested
in CAM therapies that will enhance the effectiveness
of their conventional treatment protocols and mediate
potential side effects 14 such as fatigue, nausea and
vomiting, and anxiety. However, the already complex
decision about whether to use CAM is challenged by
concerns held by some patients and their health pro-
fessionals regarding the potential risks posed by inap-
propriate CAM use 14,16,37.
2.2.2 Gathering and Evaluating CAM Information
During the initial phase of taking stock of available
treatment options and identifying a personal interest in
CAM, cancer patients begin to gather and evaluate in-
formation about the possible role of CAM in their can-
cer experience. Because the decision-making process
is highly dependent on the patient’s unique contextual
factors, the process of gathering and evaluating infor-
mation is highly variable across individuals.
For some cancer patients, particularly those who
feel overwhelmed by their diagnosis, the information
gathering and evaluation phase is a passive process in
which they seek information only about the CAM thera-
pies that they have had previous experience with or
that are recommended by a trusted health professional,
family member, or friend 14,15,18. Other cancer patients
take on a more active role in which they engage in an
extensive and iterative information-seeking and evalu-
ation process related to a diverse range of CAM thera-
pies. This process often continues throughout their
cancer journey and is revisited at key milestones, such
as at the end of conventional cancer treatment and at
diagnosis of recurrence 14,18,35. For these individuals,
the search for CAM information is motivated by their
information needs, including the potential risks and
benefits of CAM use, the likelihood of negative inter-
actions of specific CAM therapies (typically natural
health products) with conventional treatments (that is,
chemotherapy, radiation, hormone therapy), the appro-
priate timing of CAM use in the conventional cancer
treatment trajectory, and the availability and financial
cost of specific therapies 14,15,18.
The type of evidence privileged by cancer patients
in making CAM decisions varies widely and includes
professional advice, the scientific literature, anecdotes
about CAM use from social networks, the Internet, and
previous personal experiences with CAM 14,35,38. As a
result, patients seek information about CAM from a
multitude of sources, although there is a preference to
seek assistance from trusted individuals who are per-
ceived as being credible, such as oncologists, family phy-
sicians, or regulated CAM practitioners (a naturopathic
physician, for instance) 14,16,39. Whether these health
professionals have the training, knowledge, or interest to
discuss CAM therapy options with cancer patients, how-
ever, is discussed in elsewhere in this issue 40.
The information gathering and evaluation phase can
be an anxiety-provoking experience. Some individualsBALNEAVES et al.
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are able to control the amount of information they ob-
tain about CAM by restricting their search to a limited
number of therapies or by avoiding certain resources,
such as the Internet, but others report feeling over-
whelmed by the amount of CAM information they ac-
quire 14,18. Some patients struggle to make sense of
the often contradictory information that exists about
CAM 14,41, and they report being particularly distressed
about the lack of consensus between and among their
CAM and conventional health professionals about the
implications of CAM use. This conflict causes pro-
found anxiety in some cancer patients who are fear-
ful of making the “wrong” treatment decision that
could have potentially serious consequences regard-
ing their survival.
2.2.3 Making a CAM Decision
How cancer patients ultimately reach a decision about
CAM varies considerably between individuals and along
the cancer trajectory. This complex process, labelled
“bridging the gap” by Balneaves et al. 14, involves can-
cer patients attempting to make sense of the disparate
advice and information they have gathered about CAM
while reflecting on their personal beliefs about cancer,
treatment, and healing.
In our previous work, we identified three different
types of CAM decisions.
First, individuals in the midst of conventional treat-
ment who are experiencing high anxiety and conflict
often “take it one step at a time” and postpone their
CAM decisions to later in the cancer trajectory when
they have more energy to reflect on a broader spec-
trum of treatments. This delay is particularly evident
in patients who have received limited support from their
oncology health professionals in the CAM decision-
making process. The CAM therapies chosen by these
patients are typically those that fall within the realm of
supportive care (for example, massage, relaxation
therapy) and have been associated with positive psy-
chosocial outcomes 14,18.
Second, cancer patients who have a high level of
trust in the conventional health care system engage in
a “playing it safe” decision-making process in which
the advice of their oncologists is privileged throughout
the cancer trajectory. Only CAM therapies that can be
easily incorporated into their conventional treatment
protocol are chosen. Frequently, these patients perceive
their cancer diagnosis to be “too serious to play around
with” and are hesitant to use any therapies, particu-
larly natural health products, that may negatively in-
teract with their conventional treatment 14,42.
In contrast, a third group of cancer patients is able
to “bring it all together” and make treatment decisions
that incorporate CAM as part of their treatment plan
with minimal conflict and anxiety. These individuals
often report having a life-long commitment to CAM use
that precedes their diagnosis, and they believe that CAM
therapies are natural, supportive of the body’s innate
ability to heal, and better able to holistically address
physiologic and psychosocial needs than conventional
care can 14,35,43. However, some of these patients have
described feeling “pushed” towards CAM as result of
their beliefs about conventional cancer treatments be-
ing “toxic,” “poisonous,” or immunosuppressive 21,37.
Still others have turned toward CAM because of their
dissatisfaction with conventional care, including the
quality and quantity of their interactions with health
professionals, the adverse effects of conventional
treatment, and their experiences with ineffective
therapies 16,35,37,44,45. These latter patients are most
at risk of abandoning conventional care in lieu of al-
ternative treatments.
2.2.4 Revisiting the CAM Decision
As patients move through the cancer trajectory and
reach the end of their conventional treatment protocol,
many revisit the CAM decisions made following their
diagnosis and during adjuvant treatment. For some in-
dividuals, this reflection is a consequence of feeling as
if they have “fallen off the cliff” as they lose the fre-
quent contact they have had with their oncology health
professionals during active treatment 46. Adding CAM
therapies to their health care repertoire allows these
individuals to feel as if they are “still doing something”
and helping their bodies recover from the trauma of
chemotherapy and radiation. Other cancer patients see
the end of conventional treatment as opening the door
to specific CAM therapies, especially natural health
products, which were discouraged while they were
undergoing treatment because of fears of negative in-
teractions 14. Lastly, the completion of conventional
treatment also liberates patients from what can be an
extensive commitment of time and physical and emo-
tional energy; it gives them the opportunity to explore
new treatment options that were too overwhelming to
consider at the beginning of the illness experience.
Cancer patients also revisit their CAM decisions in
response to new information received regarding dis-
ease progression and prognosis 14,18. The identifica-
tion of a recurrence or metastases can result in some
individuals returning to the taking-stock phase of the
decision-making process to reconsider their CAM de-
cisions and perhaps expand their search for CAM thera-
pies, including more alternative forms of treatment.
Others interpret disease progression as a sign of inef-
fectiveness, and they withdraw or significantly alter
their CAM regimen. Conversely, results suggestive of
remission or tumour regression can encourage some
individuals to maintain or increase their use of CAM.
Lastly, the growing field of CAM research is pro-
viding new data on the efficacy and safety of specific
CAM therapies on almost a daily basis. This informa-
tion is rapidly translated to cancer patients and oncol-
ogy health professionals through the media, scientific
journals, and research-based databases [for example,
Natural Standards (www.naturalstandard.com)]. For
individuals for whom scientific evidence is an impor-
tant consideration in their treatment decisions, suchPATIENT DECISION-MAKING ABOUT CAM
CURRENT ONCOLOGY—VOLUME 15, SUPPLEMENT 2
S98
information may encourage their exploration of prom-
ising CAM therapies or their withdrawal from prod-
ucts or practices suggested to be ineffective or
potentially harmful 14,38.
3. SUMMARY
Our review of the CAM decision-making process (see
Figure 1) highlights the fact that CAM decisions are
highly individualized, complicated, and multifaceted,
and that they involve dynamic processes that vary
throughout the cancer trajectory. The decision to use—
or not to use—CAM is not a one-time whimsical deci-
sion; instead, it is a decision that leads cancer patients
to reflect on their unique personal and social context
and to ponder how CAM may fit with their values, be-
liefs, and specific health care needs. As the individual
and social contexts of patients change, the appropri-
ateness of select CAM therapies in their treatment regi-
men also changes. Decisions about CAM are not static;
rather, they are dynamic entities that require assess-
ment and follow-up by health professionals throughout
a patient’s illness.
Recognizing that CAM decision-making can be an
anxiety-laden experience for patients suggests the need
for ongoing decision and information support by oncol-
ogy health professionals from diagnosis through survi-
vorship—and for some individuals, through end of life.
Research indicates that CAM decisions coincide with
patients’ decisions about conventional treatment, with
many individuals regarding conventional and CAM thera-
pies as part of the same continuum of care 14,18. As a
consequence, cancer patients often assume that dis-
cussions about treatment options with their oncology
health professionals will include both conventional and
CAM therapies. However, oncology health profession-
als are often hampered in these types of discussions
because of the limited evidence that supports the safety
and efficacy of many CAM therapies in the context of
conventional cancer care and because of the lack of
integration of CAM education into their professional
training programs 47,48.
Despite the need for additional research and pro-
fessional education on CAM, it is essential that oncol-
ogy health professionals begin a dialogue with patients
that focuses not just on individual CAM therapies, but
also on how to make treatment decisions that acknowl-
edge scientific evidence and each patient’s beliefs,
values, and sociocultural contexts.
A dialogue regarding CAM-related treatment deci-
sions would ideally be an ongoing discussion that cor-
responds with key milestones in a patient’s illness, such
as diagnosis, end of conventional treatment, and re-
currence or metastasis. A key element of patient-cen-
tered decision support is an assessment of an
individual’s preferred level of engagement in the deci-
sion-making process and preferred degree of involve-
ment of their oncology health professionals. Further,
recognizing the individual contexts of patients, including
pre-existing beliefs about healing, previous experiences
with conventional medicine and CAM, and the influ-
ence of significant others and the surrounding commu-
nity, is also essential. Assessing patient goals related
to CAM use is also important and can illuminate im-
portant belief systems and experiences that need to be
acknowledged in tailoring decision support. Although
some patients may be interested in using CAM for cura-
tive reasons and to address the side effects of conven-
tional treatment, other patients may be pursuing CAM
to preserve hope in the face of a terminal prognosis. In
addition, acknowledging the potential barriers to CAM
use can help patients consider the fuller implications
of using CAM therapies beyond the physiologic effect
and their own physical limitations in using a diverse
range of therapies.
Verhoef, Boon, and Page 40 provide further sug-
gestions regarding how oncology health professionals
can communicate with patients about CAM. As research
in this field continues, we can expect to see evidence-
based decision-support strategies emerge, such as de-
cision-support aids and counselling strategies that will
assist patients and professionals alike in the CAM deci-
sion-making process.
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